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Summary
Objective: To critically analyze the existing literature relating to autologous chondrocyte implantation (ACI) and thereby to ascertain whether
the technique is clinically effective and safe.
Methods: Using predeﬁned criteria, we searched a number of automated databases, such as MEDLINE, EMBASE, Cochrane, CRD, etc., for
relevant articles, which were then analyzed by two independent reviewers.
Results: Three clinical trials and nine case series were evaluated. The clinical trials yielded no evidence that ACI was superior to the thera-
peutic alternatives with which it was compared. In contrast, the case series revealed an improvement in patients. However, as with the clinical
trials, the follow-up periods were usually very short. In general, few adverse effects were observed, indicating that ACI is a safe technique.
Conclusion: Available data afford no evidence that ACI is more effective than other conventional techniques in treating chondral lesions of the
knee.
ª 2005 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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The prevalence of chondral lesions has been estimated to
be around 60e63%, with the medial femoral condyle and
the patella being the most commonly affected sites1,2. How-
ever, the true incidence of damage to knee-joint cartilage is
not known with any degree of certainty, since the mani-
fested lesions may arise directly or indirectly from other
knee injuries sustained months or even years previously3.
In recent years, many diverse surgical procedures have
been developed to treat articular cartilage defects of the
knee4 or at least to bring symptomatic relief. In fact, relief
of symptoms and an improvement in functionality are the
main reasons for performing these procedures. Although
such interventions aim to prevent the expansion of lesions
and to induce the regeneration of cartilage, they can at best
delay a progression to osteoarthritis or the necessity for
joint replacement. These techniques can be divided into
four categories (Table I): (1) symptomatic treatment; (2)
stimulation of bone marrow-derived cells; (3) chondrogene-
sis within transplanted tissue/cells; and (4) transplantation
of osteochondral plugs. These procedures are rendered
necessary by the limited intrinsic capacity of cartilage tissue
to repair spontaneously. The various treatment strategies
utilize or draw on tissue cells whose potential for
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Received 11 April 2005; revision accepted 31 July 2005.47differentiation theoretically permits their transformation into
chondrocytes and the neoformation of cartilage.
Autologous chondrocyte implantation (ACI) falls within
the group of therapies that aim to induce chondrogenesis
within transplanted tissue or cells. The technique is imple-
mented in two steps. During the ﬁrst intervention, wafers
of articular cartilage are harvested from a non-load-bearing
region of bone. The excised tissue is then cultured until suf-
ﬁcient chondrocytes are available for implantation. During
the second intervention, the chondral lesion is surgically
prepared and covered with a periosteal ﬂap, which is su-
tured to the surrounding cartilage tissue. The cultured chon-
drocytes are then injected beneath the ﬂap, which is sealed
peripherally with a biological ﬁbrin glue5.
This systematic review has sought to assess the efﬁcacy
and safety of ACI in treating chondral lesions of the knee.
Methods
DATA SEARCH
We conducted a bibliographic search in a number of
databases for relevant articles published between January
1994 and December 2004. The databases included were
Medline and Premedline, Embase, Health Technology
Assessment (HTA), Latinoamerican and Caribbean Litera-
ture in Health Sciences (LILACS), Medical Spanish Index
(IME), Biomed Central, NHS Economic Evaluation Data-
base (NHS EED) and Database of Abstracts of Reviews
of Effectiveness (DARE). The Cochrane Collaboration’s da-
tabase on systematic reviews was likewise consulted. All
references cited in the selected papers were searched
manually.
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To improve the comparability and quality of the articles
considered in our evaluation, the following inclusion criteria
were established. (1) In terms of study design, we included
systematic reviews, clinical trials, meta-analyses, cohort
studies, caseecontrol studies and case series. When, in
a case series, new patients were being added with time, only
the most recent publication was evaluated in order to avoid
including the same individual more than once. (2) In terms
of sample size, we included studies with more than 20 pa-
tients. (3) In terms of study objectives, we included any re-
search that aimed to analyze the efﬁcacy and/or safety of
ACI. (4) In terms of outcome variables, we included studies
that measured clinical, histological and/or lifestyle
outcomes.
We excluded all those studies in which the lesion was lo-
cated at any site other than the knee, as well as in vitro or
animal studies. Articles published in English, Spanish,
French, Portuguese and Italian were considered.
DATA ANALYSIS
Papers were independently reviewed by two researchers,
who then jointly decided which were to be included. The
quality of primary studies was assessed using the United
States Preventive Services Task Force classiﬁcation6. Out-
comes could not be analyzed using a meta-analysis, since
only three clinical trials were included, and in each of these
the outcome variables were different.
Results
Application of our inclusion/exclusion criteria to the litera-
ture yielded four systematic reviews3,7e9, nine original pa-
pers10e18, and two cost analyses19,20. Most of the articles
originated from the United States and Sweden. Among
the papers that compared ACI with other techniques, one
study was excluded for having used a reabsorbable bovine
collagenous membrane in a matrix-guided ACI (MACI) ap-
proach and for being written in German21. Of the papers
that described the outcome in case series, four studies
were excluded: two because they reported on the outcome
of patients who were included in a later report5,22, and two
because they included fewer than 20 patients23,24.
Three randomized clinical trials were included that com-
pared ACI with the microfracturing technique10, the trans-
plantation of osteochondral cylinders11 and mosaicplasty12
(see Table II). The study conducted by Knutsen et al.10,
which compared ACI with the microfracturing technique,
Table I
Methods used in the surgical management of articular cartilage
defects
Symptomatic treatment Lavage
Debridement
Stimulation of bone
marrow-derived cells
Bridie drilling
Microfracturing
Superﬁcial abrasion
Deep abrasion or spongiolization
Chondrogenesis of tissue cells Periosteal grafting
Perichondral grafting
ACI
Transplantation of
osteochondral plugs
Allografting
Autografting (mosaicplasty)involved 80 patients. While clinical outcomes were very sim-
ilar for both techniques, lifestyle outcomes at 2 years were
better in patients who had undergone microfracturing. In
both groups, patients under 30 years of age had better clin-
ical outcomes. Chondrocyte-graft failure occurred in three
cases. The study performed by Horas et al.11, which com-
pared ACI with the transplantation of osteochondral cylin-
ders, included 40 patients who were followed up for 2
years. Both treatments led to improvements, but recovery
was much slower in the ACI group. Furthermore, graft fail-
ures occurred in this group. In the study conducted by Bent-
ley et al.12 (ACI vs mosaicplasty) a total of 100 patients
were monitored for 19 months. Outcomes were rated as
good or excellent in 82% of the ACI patients and in 69%
of the mosaicplasty cases. Each of the ﬁve patellar mosaic-
plasties failed, but there were no graft failures in the ACI
group. Porcine membranes rather than the usual periosteal
patches were used in this study.
In the case series, the number of patients who had under-
gone ACI was slightly higher and these individuals had
been followed up for a longer time (Table II). The study con-
ducted by Peterson and Minas13 in 2003 included 58 pa-
tients, who had been monitored for a mean period of 5.6
years. Two years after the intervention, good or excellent
outcomes were achieved in 91% of the patients, and these
results were maintained with time. Only one graft failure
was reported. Another study performed by Peterson et al.
in 200214 included 61 patients, who were followed up for
a mean time of 7.4 years. Overall clinical outcomes were
good or excellent in 82% of the patients at 2 years and in
83% after more than 5 years. The worst results were
achieved when the lesion was located in the patella. Ad-
verse effects occurred in 10 patients, mostly during the ﬁrst
2 years, but there were no instances of graft rejection. An
earlier study published by Peterson et al.15 (in 2000) included
94 patients who had been followed up for 2e9 years. Good
or excellent clinical outcomes were achieved in 76% of the
patients. The best results were obtained in individuals with
an isolated condylar lesion and the worst in those who had
multiple defects or trochlear lesions. Outcomes in the patel-
la were poor and graft failure occurred in seven cases. The
study conducted by Minas16 included 169 patients, who
were treated between 1995 and 1999. Approximately 50%
of the patients had undergone previous treatment; 107 pa-
tients were followed up for 1 year and 56 for 2 years. In
the groups with the most complex lesions, a (signiﬁcant) im-
provement in lifestyle was observed at 2 years. Graft fail-
ures occurred in 13 patients. The study performed by
Micheli et al.17 included 50 patients who had been treated
at different hospitals and followed up for 3 years. The con-
dition of the patients was deemed to be improved in 84% of
cases, unchanged in 8% and worse in 8%. The degree of
improvement increased with time. Graft failure occurred in
three patients. In the study conducted by Erggelet et al.18
24 patients were followed up for 6 months to 2 years. They
experienced an improvement in their condition but few had
been followed up for more than 6 months. There were no
graft failures.
Four systematic reviews were included in our evaluation.
These works were published not by scientiﬁc journals but by
different institutions. The review published in November
2004 by the National Institute for Clinical Excellence
(NICE)7 deduced that the clinical trials undertaken had not
yielded consistent evidence of the effectiveness of ACI.
Their cost analysis revealed no reliable evidence that the
procedure was cost effective. The principal conclusions of
the NICE review were that the ACI technique should not
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lm, but not on
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No conﬂict of interests.
I
Bentley et al., es were achieved
and in 69%
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1Table II
Description of the primary studies included in this systemati
ar Design and follow-up period Setting and sample size Principal outc
, 200410 Randomized clinical trial: patients
treated by ACI vs patients treated
by microfracturing, 2 years.
Norway, 80 patients;
40 in each study group.
Signiﬁcant improvements
without observable differen
questionnaire revealed im
be greater in patients who
microfracturing.
00311 Randomized clinical trial: patients
treated by ACI vs patients treated
by transplanted osteochondral
cylinders, 2 years.
Germany, 40 patients;
20 in each study group.
The recovery of ACI patie
cantly worse on the Lysho
other scales.
200312 Randomized clinical trial: patients
treated by ACI vs patients treated
by mosaicplasty, 19 months.
United Kingdom, 100
patients: 58 treated
by ACI and 42 by
mosaicplasty.
Good or excellent outcom
in 88% of the ACI patients
of the mosaicplasty patien
were not signiﬁcant.
Minas, 200313 Case series, 5.6 years. Sweden, 58 patients. Good or excellent outcom
in 91% of the patients acc
Brittberg’s score.
l., 200214 Case series, 7.4 years. Sweden, 61 patients. Good or excellent outcom
in 83% of the patients afte
l., 200015 Case series, 2e9 years. Sweden, 101 patients. Good outcomes were ach
the patients according to B
6 Case series, 1e2 years. USA, 169 patients. Statistically signiﬁcant imp
were achieved in patients
the SF-36 questionnaire.
200117 Case series, 3 years. USA, 50 patients. Signiﬁcant improvements
in 84% of the patients afte
., 200018 Case series, 1 year
(6e24 months).
Germany, 24 patients. Degree of improvement in
with time after intervention
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that there were no reliable long-term results. The review
published in 2003 by The Blue Cross and Blue Shield Asso-
ciation8 likewise concluded that available evidence offers
no support for the claim that ACI is better than other chon-
dral-lesion therapies. In August 2002, a systematic review
was conducted using the Cochrane methodology9, but no
study was included since there were no reports of clinical
trials. In 2001, a further systematic review published by
the National Coordinating Centre for Health Technology As-
sessment3 concluded that, on the basis of available evi-
dence, ACI should be classiﬁed as an experimental
technique and that it was, moreover, more costly than other
procedures.
Discussion
Only a few published studies deal with the efﬁcacy of ACI.
The three clinical trials evaluated do not permit to draw any
deﬁnitive conclusions with respect to the greater efﬁciency of
this vs other techniques used in the treatment of chondral
lesions. Although the case series yields good results, it
nevertheless lacks causal force. The systematic reviews
are more categorical in their conclusions, stating that this
technique should remain at the experimental level until fur-
ther studies are published.
Although the dearth of published clinical trials is regretta-
ble, in practice, this type of study is difﬁcult to undertake. In
the case of ACI, an additional difﬁculty is posed by the fact
that the technique calls for two steps (arthroscopy and open
surgery). Hence, with respect to the procedure itself, blinding
is practically impossible, although this limitation does not ap-
ply to a histological or radiological assessment of the out-
come. It is noteworthy that the clinical trials are all of recent
date and do not coincide with the time when the technique
was ﬁrst introduced. Although the ﬁrst study appeared in
19945, the ﬁrst clinical trial was not published until 2003. In
none of the reported clinical trials was ACI compared with
conservative treatment strategies. Another aspect that greatly
hampers a weighting of the effectiveness of ACI is that the
basis for comparison differed in the three clinical trials (mi-
crofracturing10, transplantation of osteochondral cylinders11
and mosaicplasty12). The trial reported by Knutsen et al.10
was the best conducted of the three, although the article
does not specify the type of failure suffered by the patients
who were excluded from the study. Horas et al.11 furnish
no information with respect to either the patient randomiza-
tion scheme implemented or the inclusion/exclusion criteria.
The best outcome was achieved in the trial conducted by
Bentley et al.12, which compared ACI with mosaicplasty.
However, this study suffered from the greatest methodolog-
ical shortcomings of the three. It furnished no information
with respect to either the method used to randomize the pa-
tients, the type of surgery that the patients had previously un-
dergone, the scales used for clinical assessment, or the
number of mosaicplasty patients selected for biopsy. This
was the only trial that had been funded by industry.
The primary studies evaluated were of heterogeneous
design. They differed with respect to the patient-inclusion
criteria, knee-assessment scales, age ranges, and follow-
up periods. An additional difﬁculty encountered in the as-
sessment of outcomes was that several of the papers eval-
uated have been published by the same research group, so
that results pertaining to the same patients may well have
been duplicated. Indeed, the ﬁrst patients who underwent
ACI5 are known to have been later in a larger case series15.Speciﬁc limitations of some of the case series reported by
Peterson et al.14 include a reluctance of patients to undergo
biopsy, the performance of simultaneous interventions, and
no description of adverse effects. These factors contribute
to a high subjectivity. Minas16 does not indicate the number
of biopsies that were performed. Furthermore, many of the
patients underwent concomitant interventions and only
a third of the cases initially included were monitored for 1
year. Another factor that complicates an interpretation of
the ﬁndings is that different knee-assessment scales have
been used to measure the same effect in different studies
yielding different results.
Other problems reside in the standardization of the tech-
nique and its indications. Thus, there is no general consen-
sus on the size of the lesions that qualify for ACI therapy.
However, most authors seem to agree that the best out-
comes are achieved for lesions larger than 2 cm2 and that,
in general, the mean size could be set at 5 cm2,16. Further-
more, the patients included in the studies evaluated differed
greatly in age (range: 18e50 years). Neither motivation nor
the capacity for rehabilitation is the same in the different age
brackets, and the characteristics of the joint tissue may vary
tremendously between these. The studies reviewed fail to
consider this point, albeit that differences in outcome have
been reported for patients above and below 40 years of
age10,16.
A great heterogeneity exists with respect to the location
of the lesion in the knee joint. In the studies reviewed, out-
comes have been observed to vary according to the site of
the defect, with the best results being generally recorded for
lesions located in the femoral condyles and the worst for
those located in the patella and trochlea14e17. In the case
of patellar lesions, two possible complications must be
borne in mind, namely, patellofemoral malalignment and
the presence of chondromalacia patellae. To achieve a good
outcome, the malalignment must be corrected and the
tissue debrided15.
Another limitation of existing studies relates to the follow-
up time. No long-term results related to ACI are available.
The mean follow-up time was longest (7.4 years) in one
of the studies conducted by Peterson et al.14 But in those
performed by the other investigators, patients were moni-
tored for no longer than 2e3 years. In all but two stud-
ies12,18, the shortest follow-up time did not lie below 2 years.
A key aspect in assessing any technique is patient reha-
bilitation. Many reports reproduce the complete rehabilita-
tion protocol that patients are required to follow post-
implantation, but none furnish speciﬁc, measurable and ob-
jective data with respect to the improvements achieved.
In some of the studies, lifestyle was assessed for a mean
period of 2 years using generic tools, such as the SF-36
questionnaire. In the studies that assessed lifestyle, the
most signiﬁcant improvements related to bodily pain and
physical functioning16. When ACI was compared with the
microfracturing technique10, the outcome did not favour
ACI. On the contrary, results pertaining to physical function-
ing were signiﬁcantly better in patients who had undergone
microfracturing.
Insofar as the safety of the technique is concerned, ACI
poses no threat. The most important side effect is graft re-
jection, which occurs in a very low percentage of patients
(0%12 to 7.6%16). Other less serious adverse effects have
also been described, such as swelling, haemorrhage and
arthroﬁbrosis.
Conﬂict of interests is an issue that calls for special con-
sideration. In the studies evaluated, the company tasked
with culturing the chondrocytes had furnished some sort
51Osteoarthritis and Cartilage Vol. 14, No. 1of aid (funding or training) to one or more members of the
research team. It has been noted that in studies where there
is no conﬂict of interests, outcomes tend to be somewhat
worse, which was indeed the case with the two clinical trials
that fell in this category.
In conclusion, although ACI is a safe technique, available
data are not indicative of its being more effective than other
therapeutic strategies in the treatment of chondral lesions of
the knee. Moreover, ACI is a relatively costly procedure,
since it requires two interventions and cell culturing in vitro.
These considerations place ACI at a disadvantage when
compared to conventional techniques.
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